Citizens JMP downgraded CureVac (CVAC) to Market Perform from Outperform without a price target after the company agreed to be acquired by BioNTech (BNTX) . Under the terms of the agreement, each CureVac share will be exchanged for $5.46 in BioNTech shares, resulting in an implied aggregate equity value for CureVac of $1.25B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
- M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal
- Morning Movers: CureVac skyrockets after $1.25B deal to be acquired by BioNTech
- M&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer Pipeline